Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

TL;DR

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Moderna and Merck report that adding personalized mRNA vaccine intismeran to Keytruda reduced the risk of melanoma recurrence or death by 42% in a Phase 3 trial, compared with Keytruda and placebo. At two years, 82% of patients in the vaccine group were alive without recurrence, versus 70% in the comparison group. The companies’ announcement does not provide full trial data, and the vaccine is not established here as an approved treatment.

Moderna and Merck say their personalized mRNA cancer vaccine, intismeran, reduced the risk of melanoma recurrence or death when given with Keytruda, compared with Keytruda plus placebo in a Phase 3 trial. At two years, 82% of patients who received the vaccine combination were alive without recurrence, compared with 70% in the control group; the companies reported a 42% reduction in the risk of recurrence or death.

The treatment, also called mRNA-4157, was tested alongside pembrolizumab, sold as Keytruda, in people with melanoma that had been surgically removed. The comparison group received Keytruda with a placebo. The reported 42% figure describes a relative reduction in the risk of recurrence or death, not a 42-percentage-point difference in the share of patients who remained recurrence-free.

Researchers measured recurrence-free survival (RFS), the time patients lived without the cancer returning, and distant metastasis-free survival (DMFS), the time patients lived without the cancer returning elsewhere in the body. The companies reported that intismeran plus Keytruda lowered the risk of distant metastasis or death by 38% compared with Keytruda and placebo. At the reported assessment, 88.5% in the vaccine group were alive without distant metastasis, versus 80% in the comparison group.

The report says the results were shared through a company announcement and describes the release as rushed out. The available material does not include the full study dataset or details such as the number of participants, confidence intervals, or adverse-event rates. The results therefore should be understood as company-reported trial findings, with the strength and limits of the evidence requiring review of the complete data.

Potential Gains After Melanoma Surgery

For patients whose melanoma has been removed, treatment after surgery aims to lower the chance that the cancer will return or spread. The reported difference in two-year recurrence-free survival suggests that adding an individualized vaccine could improve outcomes beyond Keytruda alone. The findings also concern distant spread, a key measure because melanoma that returns in other parts of the body can be harder to treat.

The result is not proof that every patient would benefit, nor does the 42% relative-risk reduction mean that 42% more patients were cured. The reported two-year proportions were 82% versus 70% alive without recurrence. Clinicians and patients will need the full trial results to weigh potential benefit against side effects, treatment burden, and the time needed to make a patient-specific vaccine.

How the Personalized Vaccine Works

Intismeran is designed from the genetic profile of an individual patient’s tumor. Researchers compare genetic sequences from cancer cells and healthy cells, then select cancer-specific mutations that may help the immune system recognize the tumor. The synthetic mRNA in the vaccine encodes up to 34 selected mutations, according to the report.

The approach is paired with Keytruda, an immunotherapy that targets PD-1. The current results follow a Phase 2 study, which the source says reported a 49% reduction in recurrence-or-death risk and a 59% reduction in distant-metastasis-or-death risk over five years. The Phase 3 results reported here are not directly interchangeable with those earlier figures because the follow-up periods differ; the source says the effect in Phase 3 was less pronounced.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.””

— Dean Li, president of Merck Research Laboratories, in the companies’ announcement

Full Data and Patient Risks Await

The source material does not provide the full Phase 3 publication, the trial’s participant count, exact follow-up schedule, statistical confidence intervals, or detailed safety findings. It is also unclear from the report whether the results have been presented at a scientific meeting or reviewed by regulators. Those details are needed to assess how reliable and clinically meaningful the reported differences are across patient groups.

The announcement does not establish that intismeran is approved or available as standard treatment. The reported percentages describe outcomes at the stated trial assessment, not a guarantee for an individual patient. Longer-term follow-up will be needed to show whether the separation in outcomes persists.

Publication and Regulatory Review

The next steps are likely to include release or presentation of the complete Phase 3 data, including safety results and details of how the outcomes were measured. Any regulatory application or decision would need to be confirmed separately; the available report gives no approval timeline. Until more information is public, patients should discuss established care and trial participation with their oncology team rather than treating the announcement as a change in standard practice.

Key Questions

What does the reported 42% reduction mean?

It is a relative reduction in the risk of recurrence or death for patients receiving intismeran plus Keytruda, compared with Keytruda and placebo. The reported two-year share alive without recurrence was 82% in the vaccine group and 70% in the comparison group.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using selected mutations found in a patient’s tumor. The reported Phase 3 treatment combined it with Keytruda.

Was the vaccine tested on its own?

No. According to the report, the trial compared intismeran plus Keytruda with Keytruda plus placebo. The reported results do not show what the vaccine would do without Keytruda.

Is the vaccine approved for melanoma treatment?

The source material does not confirm approval or availability. The companies’ reported Phase 3 results are trial findings; regulatory status and any application timeline remain unclear.

What information is still needed?

The complete trial data, including participant numbers, statistical measures, longer-term outcomes, and adverse-event details, would help clinicians assess the size and reliability of the benefit and the treatment’s risks.

Source: hn